Overall, these data provide the proof-of-concept for the study of PARPis in MYC-driven MM, particularly in the relapsed disease, as single agent as well as in combination with Bortezomib, exploiting the capability of this drug to induce HR down-regulation and therefore synthetic lethality when combined with PARPis [63]. Here, MYC is linked to Miyoshi myopathy.